

=> d his

(FILE 'HOME' ENTERED AT 15:53:30 ON 11 MAR 2005)

FILE 'REGISTRY' ENTERED AT 15:53:40 ON 11 MAR 2005

L1 STRUCTURE UPLOADED

L2 STRUCTURE UPLOADED

L3 0 S L1 OR L2

L4 0 S L1

L5 8 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:55:21 ON 11 MAR 2005

L6 1 S L5

FILE 'REGISTRY' ENTERED AT 15:55:38 ON 11 MAR 2005


L7 0 S L2

L8 0 S L2 FULL

FILE 'CAPLUS' ENTERED AT 15:56:37 ON 11 MAR 2005

=> d que l5 stat

L1 STR



1

G1 O,S

G2 H,Ak

G3 COOH,CN,[@1]

Structure attributes must be viewed using STN Express query preparation.

L5 8 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 365479 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.04

=> d l6 bib abs hitstr

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:868433 CAPLUS  
 DN 136:20062  
 TI Preparation of heterocyclic compounds as remedies for hyperlipidemia, arteriosclerosis, diabetes, obesity, etc.  
 IN Kuwabara, Kenji; Aoki, Tomiyoshi  
 PA Nippon Shinyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 136 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090087	A1	20011129	WO 2001-JP4400	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001058841	A5	20011203	AU 2001-58841	20010525
	CA 2410382	AA	20021125	CA 2001-2410382	20010525
	EP 1295875	A1	20030326	EP 2001-932267	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011199	A	20030401	BR 2001-11199	20010525
	JP 3591514	B2	20041124	JP 2001-586275	20010525
	ZA 2002009152	A	20040211	ZA 2002-9152	20021111
	US 2003166697	A1	20030904	US 2002-276670	20021118
	NO 2002005659	A	20021125	NO 2002-5659	20021125
	US 2004162325	A1	20040819	US 2004-781475	20040217
	US 2005009785	A1	20050113	US 2004-781293	20040217
	US 2005009892	A1	20050113	US 2004-781433	20040217
	JP 2004250460	A2	20040909	JP 2004-173431	20040611
PRAI	JP 2000-156936	A	20000526		
	JP 2001-586275	A3	20010525		
	WO 2001-JP4400	W	20010525		
	US 2002-276670	A3	20021118		

OS MARPAT 136:20062

AB The title compds. R1HetDE [R1 is optionally substituted aryl or an optionally substituted aromatic heterocyclic group; Het is a divalent aromatic heterocyclic group; D is alkylene, alkenylene, alkynylene, or the like; and E is carboxyl or the like] are prepared. The compds. decrease blood triglyceride, LDL-cholesterol and blood sugar. 2-[6-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]hexyloxy]-2-methylpropionic acid at 1 mg/kg/day orally for 4 days gave 56% decrease in blood triglyceride and 14% decrease in blood sugar in mice; troglitazone at 300 mg/kg/day orally for 4 days gave 11% decrease in blood triglyceride and 9% decrease in blood sugar in mice. Formulations are given.


IT 377731-39-0P 377731-44-7P 377731-64-1P  
 377732-13-3P 377732-15-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)

RN 377731-39-0 CAPLUS


CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methyl]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 377731-44-7 CAPLUS


CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methyl]phenyl]methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 377731-64-1 CAPLUS


CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 377732-13-3 CAPLUS

CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl]phenyl]methyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 377732-15-5 CAPLUS

CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl]phenyl]methyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 377733-07-8 377733-11-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)

RN 377733-07-8 CAPLUS

CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methyl]phenyl]methyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 377733-11-4 CAPLUS

CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methyl]phenyl]methyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 377732-58-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)

RN 377732-58-6 CAPLUS

CN Oxazole, 4-[[3-[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]phenyl]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RE.CNT 12      THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 18

L9 0 L8

=> d que 19 stat

L2 STR



1

G1 O,S

G2 H,Ak

G3 COOH,CN,[@1]

Structure attributes must be viewed using STN Express query preparation.

L8 0 SEA FILE=REGISTRY SSS FUL L2

L9 0 SEA FILE=CAPLUS ABB=ON PLU=ON L8

=> => d que 113 stat

L10 31 SEA FILE=CAPLUS ABB=ON PLU=ON "KUWABARA KENJI"/AU

L11 7 SEA FILE=CAPLUS ABB=ON PLU=ON "AOKI TOMIYOSHI"/AU

L12 35 SEA FILE=CAPLUS ABB=ON PLU=ON L10 OR L11

L13 3 SEA FILE=CAPLUS ABB=ON PLU=ON L12 AND (OXAZOLE OR THIAZOLE OR HETEROCYCLIC)

=> d 1-3 bib abs

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:868433 CAPLUS  
 DN 136:20062  
 TI Preparation of **heterocyclic** compounds as remedies for  
 hyperlipidemia, arteriosclerosis, diabetes, obesity, etc.  
 IN Kuwabara, Kenji; Aoki, Tomiyoshi  
 PA Nippon Shinyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 136 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090087	A1	20011129	WO 2001-JP4400	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001058841	A5	20011203	AU 2001-58841	20010525
	CA 2410382	AA	20021125	CA 2001-2410382	20010525
	EP 1295875	A1	20030326	EP 2001-932267	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011199	A	20030401	BR 2001-11199	20010525
	JP 3591514	B2	20041124	JP 2001-586275	20010525
	ZA 2002009152	A	20040211	ZA 2002-9152	20021111
	US 2003166697	A1	20030904	US 2002-276670	20021118
	NO 2002005659	A	20021125	NO 2002-5659	20021125
	US 2004162325	A1	20040819	US 2004-781475	20040217
	US 2005009785	A1	20050113	US 2004-781293	20040217
	US 2005009892	A1	20050113	US 2004-781433	20040217
	JP 2004250460	A2	20040909	JP 2004-173431	20040611
PRAI	JP 2000-156936	A	20000526		
	JP 2001-586275	A3	20010525		
	WO 2001-JP4400	W	20010525		
	US 2002-276670	A3	20021118		

OS MARPAT 136:20062

AB The title compds. R1HetDE [R1 is optionally substituted aryl or an optionally substituted aromatic **heterocyclic** group; Het is a divalent aromatic **heterocyclic** group; D is alkylene, alkenylene, alkynylene, or the like; and E is carboxyl or the like] are prepared The compds. decrease blood triglyceride, LDL-cholesterol and blood sugar. 2-[6-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]hexyloxy]-2-methylpropionic acid at 1 mg/kg/day orally for 4 days gave 56% decrease in blood triglyceride and 14% decrease in blood sugar in mice; troglitazone at 300 mg/kg/day orally for 4 days gave 11% decrease in blood triglyceride and 9% decrease in blood sugar in mice. Formulations are given.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:453023 CAPLUS  
 DN 135:46207  
 TI Preparation of **heterocyclic** derivatives as anticancer agents  
 IN Suzuki, Toshiyuki; Aoki, Tomiyoshi  
 PA Nippon Shinyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001044195	A1	20010621	WO 2000-JP8781	20001213	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	CA 2393358	AA	20010621	CA 2000-2393358	20001213	
	AU 2001018873	A5	20010625	AU 2001-18873	20001213	
	EP 1238974	A1	20020911	EP 2000-981657	20001213	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	US 2003022884	A1	20030130	US 2002-149622	20020612	
	US 6787546	B2	20040907			
PRAI	JP 1999-354101	A	19991214			
	JP 2000-202393	A	20000704			
	WO 2000-JP8781	W	20001213			

OS MARPAT 135:46207

AB The title compds. ABDE [A is heteroaryl or an oxide thereof; B is ethenylene; D is optionally substituted phenylene; and E is a group of general formula N(COR)SO<sub>2</sub>G (G is optionally substituted phenyl; and R is heteroaryl, heteroarylmethyl), etc.] are prepared A course of 5 injections of (E)-4-(2-(2-(N-(4-methoxybenzenesulfonyl)-N-(4-(2-pyridyl)piperazino)acetylaminophenyl)ethenyl)pyridine 1-oxide dihydrochloride at 50 mg/kg i.v. gave 80% inhibition of tumor in mice. Formulations are given.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1996:448300 CAPLUS  
DN 125:132061  
TI The effect of SM-8849 on experimental arthritis in mice  
AU Nagai, Hiroichi; Takaoka, Yuko; Kuwabara, Kenji; Kamada, Hiroyuki; Kitagaki, Kunihiro  
CS Department Pharmacology, Gifu Pharmaceutical University, Gifu, 205, Japan  
SO Pharmacology (1996), 52(6), 377-386  
CODEN: PHMGBN; ISSN: 0031-7012  
PB Karger  
DT Journal  
LA English  
AB The effect of a novel **thiazole** derivative, SM-8849, on exptl. arthritis in mice was studied and compared to that of prednisolone. SM-8849 and prednisolone reduced the incidence and severity of type II collagen-induced arthritis in mice, as assayed by clin. observation and histopathol. studies. Although both agents inhibited type II collagen-induced delayed type hypersensitivity (DTH) in arthritic mice, SM-8849 did not affect the production of humoral antibodies to type II collagen. To examine the inhibitory mechanism of SM-8849, the effects on T cell-dependent allergic inflammation were studied. SM-8849 clearly inhibited T cell-dependent reactions including staphylococcal enterotoxin B (SEB)-induced arthritis, SEB-induced CD25 expression on T cells and sheep red blood cell (SRBC)-induced DTH reaction. SM-8849, however, had no effect on the production of humoral antibody forming cells in the spleen of mice immunized with SRBC. These results indicate that inhibition of type II collagen-induced arthritis by SM-8849 is mainly due to the inactivation of T cells that are related to DTH reaction.

=> => fil capl

FILE 'CAPLUS' ENTERED AT 16:07:19 ON 11 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Mar 2005 VOL 142 ISS 12

FILE LAST UPDATED: 10 Mar 2005 (20050310/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


'FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l18

L19 1 L18

=> d que l19 stat

L2 STR



1

G1 O,S

G2 H,Ak

G3 COOH,CN,[@1]

Structure attributes must be viewed using STN Express query preparation.

L16 638116 SEA FILE=REGISTRY ABB=ON PLU=ON 16.299/RID

L18 3 SEA FILE=REGISTRY SUB=L16 SSS FUL L2

L19 1 SEA FILE=CAPLUS ABB=ON PLU=ON L18

=> d bib abs hitstr

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:868433 CAPLUS  
 DN 136:20062  
 TI Preparation of heterocyclic compounds as remedies for hyperlipidemia, arteriosclerosis, diabetes, obesity, etc.  
 IN Kuwabara, Kenji; Aoki, Tomiyoshi  
 PA Nippon Shinyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 136 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090087	A1	20011129	WO 2001-JP4400	20010525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001058841	A5	20011203	AU 2001-58841	20010525
	CA 2410382	AA	20021125	CA 2001-2410382	20010525
	EP 1295875	A1	20030326	EP 2001-932267	20010525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011199	A	20030401	BR 2001-11199	20010525
	JP 3591514	B2	20041124	JP 2001-586275	20010525
	ZA 2002009152	A	20040211	ZA 2002-9152	20021111
	US 2003166697	A1	20030904	US 2002-276670	20021118
	NO 2002005659	A	20021125	NO 2002-5659	20021125
	US 2004162325	A1	20040819	US 2004-781475	20040217
	US 2005009785	A1	20050113	US 2004-781293	20040217
	US 2005009892	A1	20050113	US 2004-781433	20040217
	JP 2004250460	A2	20040909	JP 2004-173431	20040611
PRAI	JP 2000-156936	A	20000526		
	JP 2001-586275	A3	20010525		
	WO 2001-JP4400	W	20010525		
	US 2002-276670	A3	20021118		

OS MARPAT 136:20062

AB The title compds. R1HetDE [R1 is optionally substituted aryl or an optionally substituted aromatic heterocyclic group; Het is a divalent aromatic heterocyclic group; D is alkylene, alkenylene, alkynylene, or the like; and E is carboxyl or the like] are prepared. The compds. decrease blood triglyceride, LDL-cholesterol and blood sugar. 2-[6-[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]hexyloxy]-2-methylpropionic acid at 1 mg/kg/day orally for 4 days gave 56% decrease in blood triglyceride and 14% decrease in blood sugar in mice; troglitazone at 300 mg/kg/day orally for 4 days gave 11% decrease in blood triglyceride and 9% decrease in blood sugar in mice. Formulations are given.

IT 377732-03-1P 377732-35-9P 377732-36-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as remedies for hyperlipidemia, and arteriosclerosis, and diabetes and obesity)

RN 377732-03-1 CAPLUS

CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[4-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]butyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 377732-35-9 CAPLUS

CN 1,3-Dioxane-2-carboxylic acid, 2-methyl-5-[4-[5-methyl-2-(4-methylphenyl)-4-thiazolyl]butyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 377732-36-0 CAPLUS

CN 1,3-Dioxane-2-carboxylic acid, 5-[4-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-thiazolyl]butyl]-2-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT